Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
McKesson
Harvard Business School
Johnson and Johnson
McKinsey

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,375,111

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,375,111
Title:Compositions for affecting weight loss
Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance .alpha.-MSH activity.
Inventor(s): Weber; Eckard (San Diego, CA), Cowley; Michael Alexander (Portland, OR)
Assignee: Orexigen Therapeutics, Inc. (San Diego, CA)
Application Number:10/828,795
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,375,111
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Drugs Protected by US Patent 7,375,111

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Nalpropion CONTRAVE bupropion hydrochloride; naltrexone hydrochloride TABLET, EXTENDED RELEASE;ORAL 200063-001 Sep 10, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,375,111

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 388698   Start Trial
Australia 2004233846   Start Trial
Australia 2010221801   Start Trial
Canada 2522708   Start Trial
China 1784221   Start Trial
Cyprus 1119418   Start Trial
Germany 602004012403   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Colorcon
Harvard Business School
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.